NRX:CA:TSV-NurExone Biologic Inc. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.65

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.17 (+7.87%)

USD 0.16B
ARCH:CA Arch Biopartners Inc

+0.01 (+0.57%)

USD 0.11B
MIR:CA MedMira Inc

-0.01 (-5.26%)

USD 0.05B
TTI:CA Thiogenesis Therapeutics Corp.

-0.02 (-2.78%)

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

-0.22 (-17.89%)

USD 0.03B
CZO:CA Ceapro

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

+0.01 (+4.00%)

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

+0.25 (+7.35%)

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing NRX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 120.34% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.34% 95% A 95% A
Trailing 12 Months  
Capital Gain 132.14% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 132.14% 100% F 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.40% 65% D 53% F
Dividend Return 1.40% 65% D 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.95% 52% F 52% F
Risk Adjusted Return 3.04% 65% D 53% F
Market Capitalization 0.04B 87% B+ 80% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.